Therapy Areas Markets Capabilities Insights Contact Grow
Capabilities · Manufacturing & Accreditations
WHO-GMP · PIC/S

The supply chain behind every Aravis proposal.

Aravis does not manufacture. Every molecule in the portfolio is sourced from WHO-GMP and PIC/S certified manufacturing partners, verified plant by plant before it enters a proposal. What we bring to a partner conversation isn't a factory — it's the sourcing intelligence and dossier readiness that sits on top of one.

Regulatory Reach
22
Built on WHO-GMP and PIC/S certified manufacturing, the Aravis network already holds product registrations accepted by 22 national and regional regulatory authorities across four regions — dossier and compliance groundwork a new market conversation can draw on directly.

Africa (12)

Nigeria (NAFDAC) Kenya (PPB) Ivory Coast Malawi Uganda Zambia Ethiopia Gabon Rwanda Liberia Guinea (DNPM) Congo (DPM)

CIS & E. Europe (4)

  • Uzbekistan (CSPP)
  • Russia (MOH RF)
  • EAEU
  • Ukraine (PIC/S)

Asia-Pacific (4)

  • Sri Lanka (NMRA)
  • Philippines (FDA)
  • Cambodia
  • Fiji (FiMRA)

Middle East (2)

  • Kuwait
  • Yemen (MOH)
Dosage Form Capability

2,186 molecules, five manufacturing forms.

Oral Solids
1,110
Tablets & capsules
Injectables
550
Sterile injectable forms
IV Infusions
12
Large-volume parenterals
Rare capability
Inhalers & Ophthalmics
254
MDI, nasal & ophthalmic
Liquids & Topicals
260
Syrups, topicals & sachets
Documentation

Request quality documentation for a specific molecule.

On request, Aravis provides Certificate of Pharmaceutical Product (COPP), plant-level WHO-GMP and PIC/S certificates, compendial standard references, and CTD-format dossiers compiled per target market.

Dossiers are compiled per market on request — not held pre-built.